Expand SNGX Menu
SNGX MENU

SNGX Latest Press Releases

-- February 12, 2026 --

Soligenix Details Recent Progress and Upcoming Milestones PRNewswire 7:30 AM

-- January 23, 2026 --

DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event ACCESS Newswire 2:51 PM

-- December 18, 2025 --

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behet's Disease Published in Rheumatology (Oxford) PRNewswire 7:30 AM

-- December 17, 2025 --

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis PRNewswire 7:30 AM

-- December 10, 2025 --

NetworkNewsAudio Announces Audio Press Release (APR) on Final Confirmatory Clinical Study Being Done for Treatment of Rare Disease Globe Newswire 8:30 AM

-- December 5, 2025 --

Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad Globe Newswire 8:30 AM

-- December 4, 2025 --

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations Globe Newswire 8:30 AM

-- December 3, 2025 --

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space Globe Newswire 8:30 AM

-- December 2, 2025 --

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now Globe Newswire 8:30 AM

-- November 19, 2025 --

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma PRNewswire 7:30 AM

-- November 7, 2025 --

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results PRNewswire 7:30 AM

-- October 14, 2025 --

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma PRNewswire 7:30 AM

-- October 7, 2025 --

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma PRNewswire 7:30 AM

-- September 30, 2025 --

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma PRNewswire 7:30 AM

-- September 29, 2025 --

Soligenix Announces Closing of $7.5 Million Public Offering PRNewswire 4:05 PM

-- September 26, 2025 --

Soligenix Announces Pricing of $7.5 Million Public Offering PRNewswire 6:33 AM

-- September 23, 2025 --

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor PRNewswire 7:30 AM
Market Data Delayed 15 Minutes